Fortress Biotech Inc
NASDAQ:FBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beijing Funshine Culture Media Co Ltd
SZSE:300860
|
CN |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (15.1), the stock would be worth $-42 (1 983% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.8 | $2.23 |
0%
|
| Industry Average | 15.1 | $-42 |
-1 983%
|
| Country Average | 16.7 | $-46.47 |
-2 184%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
69.9m USD | -0.8 | -37.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 21.8 | 85.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 22.8 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 17.6 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 28.5 | 28.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 11.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 110.6 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 14.7 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Fortress Biotech Inc
Glance View
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
